EUVIMEDEUVIMED entdecken
Open Access

Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome

Megha Ranganathan iD, Rosalba E Sacca, Magan Trottier, Anna Maio, Yelena Kemel iD, Erin Salo-Mullen, Amanda Catchings iD, Sarah Kane iD, Chiyun Wang iD, Vignesh Ravichandran iD, Ryan Ptashkin, Nikita Mehta iD und 18 weitere

JCO Precision Oncology · 2023-05 · (7)

DOI: 10.1200/po.22.00675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-05. Verfasst von Megha Ranganathan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Lynch syndrome (LS)–associated colorectal cancer (CRC) is characterized by mismatch repair-deficiency (MMR-D) and/or microsatellite instability (MSI). However, with increasing utilization of germline testing, MMR-proficient (MMR-P) and/or microsatellite stable (MSS) CRC has also been observed. We sought to characterize MMR-P/MSS CRC among patients with LS. METHODS Patients with solid tumors with germline MMR pathogenic/likely pathogenic (P/LP) variants were identified on a prospective matched tumor-normal next-generation sequencing (NGS) protocol. CRCs were evaluated for MMR-D via immunohistochemical (IHC) staining and/or MSI via NGS. Clinical variables were correlated with MMR status using nonparametric tests. RESULTS Among 17,617 patients with solid tumors, 1.4% (n = 242) had LS. A total of 36% (86 of 242) of patients with LS had at least one CRC that underwent NGS profiling, amounting to 99 pooled CRCs assessed. A total of 10% (10 of 99) of CRCs were MMR-P, with 100% concordance between MSS status and retained MMR protein staining. A total of 89% (8 of 9) of patients in the MMR-P group had MSH6 or PMS2 variants, compared with 30% (23 of 77) in the MMR-D group ( P = .001). A total of 46% (6 of 13) of PMS2+ patients had MMR-P CRC. The median age of onset was 58 and 43 years for MMR-P and MMR-D CRC, respectively ( P = .07). Despite the later median age of onset, 40% (4 of 10) of MMR-P CRCs were diagnosed

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisPrevalenceBrain NeoplasmsMismatch Repair Endonuclease PMS2Microsatellite InstabilityNeoplastic Syndromes, HereditaryDNA Mismatch RepairProspective StudiesHumans

Substanzen

Mismatch Repair Endonuclease PMS2

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Surgery, Weill Cornell Medical College, New York, NY.
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Megha Ranganathan, Yelena Kemel, Amanda Catchings, Sarah Kane, Chiyun Wang, Vignesh Ravichandran, Nikita Mehta, Julio Garcia-Aguilar, Martin R Weiser, Michael F Berger, Diana Mandelker, Michael F Walsh, Maria Carlo, Ying L Liu, Andrea Cercek, Rona Yaeger, Leonard Saltz, Neil H Segal, Robin B Mendelsohn, Arnold J Markowitz, Kenneth Offit, Jinru Shia, Zsofia K Stadler, Alicia Latham

Förderung

  • NCI NIH HHS

Zitieren

APA

Ranganathan, M., Sacca, R. E., Trottier, M., Maio, A., Kemel, Y., Salo-Mullen, E., Catchings, A., Kane, S., Wang, C., Ravichandran, V., Ptashkin, R., Mehta, N., Garcia-Aguilar, J., Weiser, M. R., Donoghue, M. T. A., Berger, M. F., Mandelker, D., Walsh, M. F., Carlo, M., …, & Latham, A. (2023). Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome. JCO Precision Oncology. https://doi.org/10.1200/po.22.00675

Vancouver

Ranganathan M, Sacca RE, Trottier M, Maio A, Kemel Y, Salo-Mullen E, et al. Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome. JCO Precision Oncology. 2023. doi:10.1200/po.22.00675

BibTeX
@article{Ranganathan2023,
  author = {Ranganathan, Megha and Sacca, Rosalba E and Trottier, Magan and Maio, Anna and Kemel, Yelena and Salo-Mullen, Erin and Catchings, Amanda and Kane, Sarah and Wang, Chiyun and Ravichandran, Vignesh and Ptashkin, Ryan and Mehta, Nikita and Garcia-Aguilar, Julio and Weiser, Martin R and Donoghue, Mark T A and Berger, Michael F and Mandelker, Diana and Walsh, Michael F and Carlo, Maria and Liu, Ying L and Cercek, Andrea and Yaeger, Rona and Saltz, Leonard and Segal, Neil H and Mendelsohn, Robin B and Markowitz, Arnold J and Offit, Kenneth and Shia, Jinru and Stadler, Zsofia K and Latham, Alicia},
  title = {Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome},
  journal = {JCO Precision Oncology},
  year = {2023},
  number = {7},
  doi = {10.1200/po.22.00675}
}
Kostenlos starten →